171228-49-2 | Posaconazole

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$15.00	$10.00
10mg	95%	in stock	$18.00	$12.00
50mg	95%	in stock	$21.00	$15.00
250mg	95%	in stock	$25.00	$18.00
1g	95%	in stock	$53.00	$37.00
5g	95%	in stock	$177.00	$124.00
10g	95%	in stock	$323.00	$226.00
25g	95%	in stock	$628.00	$440.00

Description

• Catalog Number: AB52183
• Chemical Name: Posaconazole
• CAS Number: 171228-49-2
• Molecular Formula: C37H42F2N8O4
• Molecular Weight: 700.7774
• MDL Number: MFCD28138428
• SMILES: CC[C@H](n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OC[C@@H]1CO[C@@](C1)(Cn1cncn1)c1ccc(cc1F)F)[C@@H](O)C

Computed Properties

• Complexity: 1170
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 51
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 12
• XLogP3: 4.6

Literature

• Azole resistance in canine and feline isolates of Aspergillus fumigatus.

  Comparative immunology, microbiology and infectious diseases 20151001

• Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.

  Antimicrobial agents and chemotherapy 20140801

• Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

  Antimicrobial agents and chemotherapy 20140301

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method.

  Journal of clinical microbiology 20130801

• In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi.

  Antimicrobial agents and chemotherapy 20130401

• Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.

  PloS one 20130101

• A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20121101

• In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.

  Diagnostic microbiology and infectious disease 20121101

• Experimental murine model of disseminated infection by Saksenaea vasiformis: successful treatment with posaconazole.

  Medical mycology 20121001

• Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.

  Transplant infectious disease : an official journal of the Transplantation Society 20121001

• Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?

  Diagnostic microbiology and infectious disease 20121001

• Meningitis due to Cryptococcus neoformans: treatment with posaconazole.

  Current HIV research 20121001

• Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy.

  Transplantation proceedings 20121001

• Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole.

  Blood 20120920

• Successful treatment of cutaneous zygomycosis with extensive surgical debridement and oral posaconazole in an immunocompetent patient.

  Journal of plastic, reconstructive & aesthetic surgery : JPRAS 20120901

• Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120901

• Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.

  The Journal of antimicrobial chemotherapy 20120901

• Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains.

  Journal of clinical microbiology 20120901

• Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.

  The Annals of pharmacotherapy 20120901

• Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis.

  Transplantation 20120827

• Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.

  Transplantation 20120815

• In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.

  The Journal of antimicrobial chemotherapy 20120801

• High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis.

  The Journal of antimicrobial chemotherapy 20120801

• Characterization of an unusual ring-contraction degradant of the antifungal agent posaconazole.

  Magnetic resonance in chemistry : MRC 20120801

• Success of posaconazole therapy in a heart transplanted patient with Alternaria infectoria cutaneous infection.

  Medical mycology 20120701

• Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis.

  The Journal of antimicrobial chemotherapy 20120701

• Structural characterization of a novel degradant of the antifungal agent posaconazole.

  Journal of pharmaceutical and biomedical analysis 20120701

• EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120701

• Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi.

  International journal of antimicrobial agents 20120701

• The management of febrile neutropenia in the posaconazole era: a new challenge?

  Haematologica 20120701

• Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

  European journal of clinical pharmacology 20120601

• A murine model of Cryptococcus gattii meningoencephalitis.

  The Journal of antimicrobial chemotherapy 20120601

• Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.

  International journal of antimicrobial agents 20120601

• Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.

  Therapeutic drug monitoring 20120601

• Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.

  Journal of medicinal chemistry 20120510

• In vitro activity of Amphotericin B against zygomycetes isolated from deep mycoses: a comparative study between incubation in aerobic and hyperbaric atmosphere.

  Medical mycology 20120501

• Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

  The Journal of asthma : official journal of the Association for the Care of Asthma 20120501

• Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

  Haematologica 20120401

• Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction.

  Current medical research and opinion 20120401

• In vitro antifungal susceptibility of Malassezia pachydermatis from dogs with and without skin lesions.

  Veterinary microbiology 20120323

• Successful treatment of disseminated mixed invasive fungal infection after hematopoietic stem cell transplantation for severe aplastic anemia.

  Pediatric transplantation 20120301

• Candida kefyr fungal enteritis following autologous BMT.

  Bone marrow transplantation 20120301

• Posaconazole: when and how? The clinician's view.

  Mycoses 20120301

• Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

  Haematologica 20120301

• New species of Madurella, causative agents of black-grain mycetoma.

  Journal of clinical microbiology 20120301

• Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.

  Antimicrobial agents and chemotherapy 20120301

• Rapid and sensitive determination of posaconazole in patient plasma by capillary electrophoresis with field-amplified sample stacking.

  Journal of chromatography. A 20120224

• Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20120201

• Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole.

  Medical mycology 20120201

• Long-term treatment of invasive sinus, tracheobroncheal, pulmonary and intracerebral aspergillosis in acute lymphoblastic leukaemia.

  Infection 20120201

• A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.

  The British journal of dermatology 20120201

• Posaconazole: the case for therapeutic drug monitoring.

  Therapeutic drug monitoring 20120201

• Combination therapy for mucormycosis: why, what, and how?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120201

• Posaconazole serum level on day 2 predicts steady state posaconazole serum level.

  Therapeutic drug monitoring 20120201

• A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.

  Future microbiology 20120201

• In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.

  Mycopathologia 20120101

• Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan.

  Antimicrobial agents and chemotherapy 20120101

• Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.

  Journal of clinical pathology 20120101

• Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.

  Expert opinion on drug metabolism & toxicology 20120101

• [53-year-old woman with life-threatening complications after use of ciprofloxacin and posaconazol].

  Deutsche medizinische Wochenschrift (1946) 20120101

• Oral antifungal therapy for Fusarium-associated chronic rhinosinusitis.

  International forum of allergy & rhinology 20120101

• Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.

  BMC infectious diseases 20120101

• Cutaneous zygomycosis.

  Clinics in dermatology 20120101

• [Azole resistance in Aspergillus fumigatus in the Netherlands--increase due to environmental fungicides?].

  Nederlands tijdschrift voor geneeskunde 20120101

• Paecilomyces lilacinus and alternaria infectoria cutaneous infections in a sarcoidosis patient after double-lung transplantation.

  Acta clinica Belgica 20120101

• Advances in systemic antifungal therapy.

  Clinics in dermatology 20120101

• Triazole antifungal agents in invasive fungal infections: a comparative review.

  Drugs 20111224

• Structural determination of an unknown degradation product in posaconazole drug product using CASI technology in a Fourier transform ion cyclotron resonance mass spectrometer.

  Rapid communications in mass spectrometry : RCM 20111215

• Pneumothorax and empyema complicating Scedosporium apiospermum mycetoma: not just a problem in the immunocompromised patients.

  Irish journal of medical science 20111201

• Posaconazole for the treatment of mucormycosis.

  International journal of antimicrobial agents 20111201

• In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

  Diagnostic microbiology and infectious disease 20111201

• Posaconazole for chronic refractory coccidioidal meningitis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111201

• Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111201

• Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection.

  Therapeutic drug monitoring 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [Antifungal therapy update: new drugs and medical uses].

  Enfermedades infecciosas y microbiologia clinica 20111201

• Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.

  Tropical biomedicine 20111201

• [In vitro synergisms among hydrazones, ajoeno and posaconazole against Cryptococcus spp].

  Investigacion clinica 20111201

• A dried blood spots technique based LC-MS/MS method for the analysis of posaconazole in human whole blood samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115

• Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111101

• A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20111101

• Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist.

  Medical mycology 20111101

• Optimising absorption of posaconazole.

  Mycoses 20111101

• Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.

  Journal of clinical microbiology 20111101

• Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

  Diagnostic microbiology and infectious disease 20111101

• EUCAST technical note on posaconazole.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20111101

• Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.

  Clinical pharmacokinetics 20111101

• A common fungus, an unusual (and deadly) infection.

  The American journal of medicine 20111101

• T. asahii pulmonary infection as a complication of TNF-inhibitor and steroids: posaconazole pharmacotherapy and risk analysis.

  Journal of the Mississippi State Medical Association 20111101

• [Exophytic and ulcerative lesions on the lower limb in a Moroccan patient].

  Medicina clinica 20111015

• Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.

  Medical mycology 20111001

• In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.

  Diagnostic microbiology and infectious disease 20111001

• Update in treatment of Chagas disease.

  Current opinion in infectious diseases 20111001

• Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.

  Journal of chemotherapy (Florence, Italy) 20111001

• In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.

  Mycoses 20110901

• Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model.

  Mycoses 20110901

• Posaconazole: a new antifungal weapon.

  Reviews on recent clinical trials 20110901

• Peripheral neuropathy in patients on long-term triazole antifungal therapy.

  The Journal of antimicrobial chemotherapy 20110901

• A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease.

  The Pediatric infectious disease journal 20110901

• Rhino-orbital-cerebral mucormycosis (ROCM): a comprehensive case review.

  Aviation, space, and environmental medicine 20110901

• 74-year-old man from the pacific northwest with fever and a lung mass.

  Chest 20110901

• Disseminated nocardiosis masking an atypical zygomycosis presentation in a kidney transplant recipient.

  Transplant infectious disease : an official journal of the Transplantation Society 20110801

• Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient.

  Transplant infectious disease : an official journal of the Transplantation Society 20110801

• Fatal disseminated infection due to Scedosporium prolificans in a patient with acute myeloid leukemia and posaconazole prophylaxis.

  Leukemia & lymphoma 20110801

• Posaconazole plasma concentrations in critically ill patients.

  Therapeutic drug monitoring 20110801

• Madurella mycetomatis mycetoma treated successfully with oral posaconazole.

  Journal of chemotherapy (Florence, Italy) 20110801

• Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia.

  Mycoses 20110701

• Cavitary lung lesions in a renal transplant recipient.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701

• Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives.

  Bioorganic & medicinal chemistry letters 20110601

• Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases.

  Annals of the Academy of Medicine, Singapore 20110601

• European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.

  Bone marrow transplantation 20110501

• Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation.

  Bone marrow transplantation 20110501

• Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

  The Journal of infectious diseases 20110501

• Cerebral mucormycosis in a diabetic man.

  Connecticut medicine 20110501

• Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110401

• Aspergillus endocarditis 2003-2009.

  Medical mycology 20110401

• Retrospective survey on the off-label use of posaconazole in pediatric hematology patients.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20110401

• Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

  Antimicrobial agents and chemotherapy 20110401

• Delayed recalcitrant fungal endophthalmitis secondary to Curvularia.

  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 20110401

• Therapeutic efficacy of posaconazole against Candida glabrata in a murine model of vaginitis.

  Mycoses 20110301

• Combined therapy against murine-disseminated infection by Fusarium verticillioides.

  Mycopathologia 20110301

• Posaconazole susceptibility of clinical yeast isolates determined by an agar diffusion and microdilution method.

  International journal of antimicrobial agents 20110301

• A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.

  International journal of antimicrobial agents 20110301

• Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections.

  Clinical pharmacology and therapeutics 20110301

• Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.

  PharmacoEconomics 20110301

• Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies.

  The Journal of antimicrobial chemotherapy 20110201

• Therapeutic drug monitoring of voriconazole and posaconazole.

  Pharmacotherapy 20110201

• Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.

  Journal of clinical pharmacology 20110101

• Two new species of Mucor from clinical samples.

  Medical mycology 20110101

• Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis.

  The Journal of antimicrobial chemotherapy 20110101

• Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study.

  Mycoses 20110101

• Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.

  Mycoses 20110101

• Posaconazole: clinical pharmacokinetics and drug interactions.

  Mycoses 20110101

• Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.

  Mycoses 20110101

• Posaconazole as part of the antifungal armamentarium in the intensive care unit--case reports from a surgical ICU.

  Mycoses 20110101

• Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.

  Journal of medical economics 20110101

• Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole.

  Clinical & developmental immunology 20110101

• Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.

  European journal of medical research 20110101

• Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.

  European journal of medical research 20110101

• Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies.

  PloS one 20110101

• Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

  Advances in parasitology 20110101

• Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring.

  Acta clinica Belgica 20110101

• [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101215

• Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101215

• Use of posaconazole in the treatment of infective rhinocerebral mucormycosis.

  The Journal of laryngology and otology 20101201

• Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20101201

• In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.

  Antimicrobial agents and chemotherapy 20101201

• Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

  Antimicrobial agents and chemotherapy 20101201

• Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

  Antimicrobial agents and chemotherapy 20101201

• Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea.

  Journal of clinical microbiology 20101201

• Sixty-year-old man with slowly expanding nodular plaque on the thigh.

  Journal of the American Academy of Dermatology 20101201

• Managing invasive fungal disease in immunocompromised patients.

  Future microbiology 20101201

• Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient.

  Transplantation 20101127

• AfMkk2 is required for cell wall integrity signaling, adhesion, and full virulence of the human pathogen Aspergillus fumigatus.

  International journal of medical microbiology : IJMM 20101101

• Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

  Mycopathologia 20101101

• Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.

  Antimicrobial agents and chemotherapy 20101101

• In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.

  Antimicrobial agents and chemotherapy 20101101

• Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.

  Antimicrobial agents and chemotherapy 20101101

• Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

  Antimicrobial agents and chemotherapy 20101001

• Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.

  Antimicrobial agents and chemotherapy 20101001

• In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.

  The Journal of antimicrobial chemotherapy 20101001

• Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20101001

• Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.

  The Journal of antimicrobial chemotherapy 20101001

• Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.

  Current medical research and opinion 20101001

• Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

  British journal of clinical pharmacology 20101001

• In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.

  Chinese medical journal 20101001

• A noninvasive renal fungus ball caused by Rhizopus--a previously unreported manifestation of zygomycosis.

  Medical mycology 20100901

• Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.

  Annals of hematology 20100901

• Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.

  Antimicrobial agents and chemotherapy 20100901

• Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.

  Antimicrobial agents and chemotherapy 20100901

• Experimental murine scedosporiosis: histopathology and azole treatment.

  Antimicrobial agents and chemotherapy 20100901

• In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.

  Antimicrobial agents and chemotherapy 20100901

• Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

  Journal of clinical microbiology 20100901

• Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates.

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20100901

• Ulcerated plaque under a ruby ring in an immunosuppressed patient.

  Dermatology online journal 20100815

• Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

  The Journal of biological chemistry 20100813

• Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp.

  Medical mycology 20100801

• Posaconazole salvage treatment in paediatric patients: a multicentre survey.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20100801

• Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

  Antimicrobial agents and chemotherapy 20100801

• Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.

  The Journal of antimicrobial chemotherapy 20100701

• Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

  Antimicrobial agents and chemotherapy 20100701

• A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.

  International journal of antimicrobial agents 20100701

• Intracellular concentrations of posaconazole in different compartments of peripheral blood.

  Antimicrobial agents and chemotherapy 20100701

• Antifungal therapies in murine disseminated phaeohyphomycoses caused by Exophiala species.

  The Journal of antimicrobial chemotherapy 20100701

• Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.

  Clinical pharmacology and therapeutics 20100701

• Chagas disease: pushing through the pipeline.

  Nature 20100624

• Conazoles.

  Molecules (Basel, Switzerland) 20100609

• Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20100601

• Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis.

  Auris, nasus, larynx 20100601

• Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.

  Transplant infectious disease : an official journal of the Transplantation Society 20100601

• Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection.

  Transplant infectious disease : an official journal of the Transplantation Society 20100601

• Potential synergistic activity of antimycotic substances in combination with human platelets against Aspergillus fumigatus.

  The Journal of antimicrobial chemotherapy 20100601

• Pharmacokinetic/pharmacodynamic profile of posaconazole.

  Clinical pharmacokinetics 20100601

• Rhizopus oryzae skin infection treated with posaconazole in a boy with chronic granulomatous disease.

  The Pediatric infectious disease journal 20100601

• Mucormycosis may mimic disease relapse in Wegener's granulomatosis.

  The Journal of rheumatology 20100601

• [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20100601

• Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.

  Journal of medicinal chemistry 20100527

• Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases.

  Mycoses 20100501

• Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.

  Bone marrow transplantation 20100501

• Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

  Antimicrobial agents and chemotherapy 20100501

• Cutaneous model of invasive aspergillosis.

  Antimicrobial agents and chemotherapy 20100501

• Use of a high-resolution melt assay to characterize codon 54 of the cyp51A gene of Aspergillus fumigatus on a Rotor-Gene 6000 instrument.

  Antimicrobial agents and chemotherapy 20100501

• Skin concentrations and pharmacokinetics of posaconazole after oral administration.

  Antimicrobial agents and chemotherapy 20100501

• Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.

  Pediatric blood & cancer 20100501

• Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.

  The Journal of antimicrobial chemotherapy 20100501

• Traditional and emerging antifungal therapies.

  Proceedings of the American Thoracic Society 20100501

• [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].

  Pathologie-biologie 20100401

• Unusual presentation of chromoblastomycosis due to Cladophialophora carrionii in a renal and pancreas transplant recipient patient successfully treated with posaconazole and surgical excision.

  Transplant infectious disease : an official journal of the Transplantation Society 20100401

• In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

  Antimicrobial agents and chemotherapy 20100401

• In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes.

  The Journal of antimicrobial chemotherapy 20100401

• Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

  The American journal of tropical medicine and hygiene 20100401

• Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

  PLoS neglected tropical diseases 20100401

• Presumed Scopulariopsis brevicaulis chorioretinitis in a stem cell transplant recipient.

  Clinical & experimental ophthalmology 20100401

• Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Onychomycosis.

  Clinics in dermatology 20100304

• Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole.

  Mycoses 20100301

• Splenic hyalohyphomycosis, molecularly and immunologically consistent with invasive aspergillosis, in a patient with acute lymphoblastic leukemia.

  American journal of hematology 20100301

• Müeller-Hinton methylene blue media as an alternative to RPMI 1640 for determining the susceptibility of Cryptococcus neoformans and Cryptococcus gattii to posaconazole with Etest.

  Mycoses 20100301

• Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.

  Antimicrobial agents and chemotherapy 20100301

• Current controversies in treating invasive zygomycosis.

  Journal of pediatric hematology/oncology 20100301

• Successful triple combination therapy of disseminated absidia corymbifera infection in an adolescent with osteosarcoma.

  Journal of pediatric hematology/oncology 20100301

• Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature.

  Journal of pediatric hematology/oncology 20100301

• Sinonasal mucormycosis: case report.

  European annals of otorhinolaryngology, head and neck diseases 20100301

• Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100215

• [Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis].

  La Revue de medecine interne 20100201

• Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

  Antimicrobial agents and chemotherapy 20100201

• In vitro activity of antifungal combinations against Candida albicans biofilms.

  The Journal of antimicrobial chemotherapy 20100201

• Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

  Current medical research and opinion 20100201

• Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.

  International journal of antimicrobial agents 20100201

• Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.

  Antimicrobial agents and chemotherapy 20100201

• Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis.

  American journal of clinical oncology 20100201

• Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies.

  Mycoses 20100101

• Iatrogenic eyelid granulomata.

  American journal of therapeutics 20100101

• Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.

  Antimicrobial agents and chemotherapy 20100101

• Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.

  Antimicrobial agents and chemotherapy 20100101

• Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.

  Current medical research and opinion 20100101

• Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?

  Leukemia & lymphoma 20100101

• Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.

  Oncology 20100101

• Intermittent posaconazole regimen to treat superficial Scytalidium dimidiatum infection.

  European journal of dermatology : EJD 20100101

• Posaconazole.

  Journal of postgraduate medicine 20100101

• Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

  Drug design, development and therapy 20100101

• Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection.

  Journal of pharmaceutical and biomedical analysis 20091205

• Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.

  Antimicrobial agents and chemotherapy 20091201

• Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

  Antimicrobial agents and chemotherapy 20091201

• Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

  Antimicrobial agents and chemotherapy 20091201

• Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

  Journal of clinical microbiology 20091201

• Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects.

  Toxicologic pathology 20091201

• Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.

  Bioorganic & medicinal chemistry letters 20091201

• Successful treatment of ascending aortic graft and valve endocarditis after debulking splenectomy for invasive aspergillosis and mucor.

  The American surgeon 20091201

• Use of posaconazole in the treatment of invasive fungal  infections.

  Expert review of hematology 20091201

• Cutaneous zygomycosis caused by Saksenaea vasiformis following water-related wound in a 24-year-old immunocompetent woman.

  Mycoses 20091101

• Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.

  Antimicrobial agents and chemotherapy 20091101

• Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.

  Antimicrobial agents and chemotherapy 20091101

• Posaconazole attenuates leukotriene B4 release and uptake of calcium by chemoattractant-activated human neutrophils: a potential strategy to control neutrophil-mediated inflammation.

  The Journal of antimicrobial chemotherapy 20091101

• [Non-fatal disseminated mucormycosis in a solid organ transplant].

  Revue des maladies respiratoires 20091101

• Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.

  Surgical infections 20091001

• Atypical Aspergillus flavus isolates associated with chronic azole therapy.

  Journal of clinical microbiology 20091001

• Disseminated zygomycosis with involvement of the central nervous system.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

• In vitro activity of antifungals against Zygomycetes.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

• Current experience in treating invasive zygomycosis with posaconazole.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

• Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

• Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20090901

• ZYGOMYCOSIS: current approaches to management of patients with haematological malignancies.

  British journal of haematology 20090901

• A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: Implementing fused core silica liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20090815

• Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815

• Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.

  Bone marrow transplantation 20090801

• In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

  Antimicrobial agents and chemotherapy 20090801

• Efficacy of triazoles in a murine disseminated infection by Candida krusei.

  Antimicrobial agents and chemotherapy 20090801

• Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090801

• What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?

  Antimicrobial agents and chemotherapy 20090801

• Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Posaconazole-induced topiramate toxicity.

  Annals of internal medicine 20090721

• Treatment of intestinal and hepatic mucormycosis in an immunocompromized child.

  Pediatric blood & cancer 20090701

• Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

  Antimicrobial agents and chemotherapy 20090701

• Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.

  Antimicrobial agents and chemotherapy 20090701

• Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.

  Journal of medicinal chemistry 20090625

• Recent advances in the management of mucormycosis: from bench to bedside.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090615

• Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl.

  Pediatric diabetes 20090601

• Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis.

  Therapeutic drug monitoring 20090601

• Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.

  FEMS yeast research 20090601

• Cutaneous infection caused by Macrophomina phaseolina in a child with acute myeloid leukemia.

  Journal of clinical microbiology 20090601

• Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.

  Journal of clinical pharmacy and therapeutics 20090601

• Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia.

  Mycoses 20090501

• Triazole-resistant candidaemia following posaconazole exposure.

  International journal of antimicrobial agents 20090501

• Posaconazole therapeutic drug monitoring: a reference laboratory experience.

  Antimicrobial agents and chemotherapy 20090501

• The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.

  The Journal of antimicrobial chemotherapy 20090501

• Diagnosis and treatment of aspergillosis in children.

  Expert review of anti-infective therapy 20090501

• Rhinocerebral mucormycosis.

  British journal of hospital medicine (London, England : 2005) 20090501

• Trichosporon mucoides fungemia in a liver transplant recipient: case report and review.

  Transplant infectious disease : an official journal of the Transplantation Society 20090401

• Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

  Journal of clinical microbiology 20090401

• Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

  Antimicrobial agents and chemotherapy 20090401

• Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.

  Antimicrobial agents and chemotherapy 20090401

• A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.

  Diagnostic microbiology and infectious disease 20090401

• Posaconazole for bone-invading rhinomaxillary mucormycosis.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20090401

• Posaconazole-increased vincristine neurotoxicity in a child: a case report.

  Journal of pediatric hematology/oncology 20090401

• Rational modification of a candidate cancer drug for use against Chagas disease.

  Journal of medicinal chemistry 20090326

• Omeprazole significantly reduces posaconazole serum trough level.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090315

• Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.

  Medical mycology 20090301

• Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

  Antimicrobial agents and chemotherapy 20090301

• Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery.

  Medical mycology 20090301

• Effects of oral posaconazole on the pharmacokinetics of sirolimus.

  Current medical research and opinion 20090301

• Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.

  Expert review of anti-infective therapy 20090301

• Posaconazole mono- or combination therapy for treatment of murine zygomycosis.

  Antimicrobial agents and chemotherapy 20090201

• Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

  Antimicrobial agents and chemotherapy 20090201

• Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus.

  The Journal of antimicrobial chemotherapy 20090201

• Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.

  Medical mycology 20090201

• Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090201

• Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.

  Clinical therapeutics 20090201

• [Amphotericin and posaconazole for gastrointestinal mucormycosis].

  Revista espanola de anestesiologia y reanimacion 20090201

• Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report.

  Mycoses 20090101

• Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole.

  Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20090101

• Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

  Antimicrobial agents and chemotherapy 20090101

• Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.

  Antimicrobial agents and chemotherapy 20090101

• International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.

  Antimicrobial agents and chemotherapy 20090101

• Voriconazole and posaconazole resistant Candida pelliculosa fungemia after cardiac surgery.

  The Pediatric infectious disease journal 20090101

• An increasing trend of cutaneous zygomycosis caused by Mycocladus corymbifer (formerly Absidia corymbifera): report of two cases and review of primary cutaneous Mycocladus infections.

  Medical mycology 20090101

• A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20090101

• Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports.

  In vivo (Athens, Greece) 20090101

• Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.

  Clinical drug investigation 20090101

• Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature.

  Transplant infectious disease : an official journal of the Transplantation Society 20081201

• Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20081201

• Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.

  European journal of haematology 20081201

• Posaconazole concentrations in the central nervous system.

  The Journal of antimicrobial chemotherapy 20081201

• Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.

  The Journal of antimicrobial chemotherapy 20081201

• Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081201

• [Trends in development of new antifungal agents in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20081201

• Clinical experience with posaconazole in patients with invasive mucormycosis: a case series.

  Puerto Rico health sciences journal 20081201

• [Invasive pulmonary mucormycosis with invasion of the thoracic spine in a patient with myelodysplastic syndrome].

  Revue medicale de Liege 20081201

• Disseminated Saksenaea vasiformis in an immunocompetent host.

  The Medical journal of Australia 20081103

• Posaconazole as first line treatment for disseminated zygomycosis.

  Mycoses 20081101

• [Posaconazole: another triazole antifungal of the new generation?].

  Deutsche medizinische Wochenschrift (1946) 20081101

• In vitro susceptibility of Pythium insidiosum and a Lagenidium sp to itraconazole, posaconazole, voriconazole, terbinafine, caspofungin, and mefenoxam.

  American journal of veterinary research 20081101

• Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.

  PLoS medicine 20081101

• Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation.

  International journal of antimicrobial agents 20081001

• Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation.

  Bone marrow transplantation 20081001

• Infection of the subcutis of the nose in a cat caused by Mucor species: successful treatment using posaconazole.

  Journal of feline medicine and surgery 20081001

• Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.

  Diagnostic microbiology and infectious disease 20081001

• Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

  Antimicrobial agents and chemotherapy 20081001

• Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

  Antimicrobial agents and chemotherapy 20081001

• Posaconazole: an oral triazole with an extended spectrum of activity.

  The Annals of pharmacotherapy 20081001

• Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

  Pharmacotherapy 20081001

• Adverse drug events complicate antifungal therapy for pulmonary aspergilloma.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20081001

• Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.

  Transplantation 20080927

• Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.

  The Journal of antimicrobial chemotherapy 20080901

• Investigation and management of an outbreak of mucormycosis in a paediatric oncology unit.

  The Journal of hospital infection 20080901

• Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.

  Journal of clinical microbiology 20080901

• Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values.

  Mycoses 20080901

• Posaconazole for paediatric patients: status of development and future perspectives.

  Mycoses 20080901

• Invasive candidiasis in the ICU: evidence based and on the edge of evidence.

  Mycoses 20080901

• Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.

  Mycoses 20080901

• Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.

  Medical mycology 20080901

• In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

  Antimicrobial agents and chemotherapy 20080801

• Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis.

  Mycopathologia 20080801

• Treatment of aspergillosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080801

• [In vitro susceptibility of isolates of Scytalidium spp. from superficial lesions against posaconazole].

  Pathologie-biologie 20080701

• MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii.

  The Journal of antimicrobial chemotherapy 20080701

• Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

  Antimicrobial agents and chemotherapy 20080701

• In vitro susceptibility of Cryptococcus gattii clinical isolates.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20080701

• In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.

  Antimicrobial agents and chemotherapy 20080601

• Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.

  Antimicrobial agents and chemotherapy 20080601

• [New systemic antifungal drugs].

  La Revue de medecine interne 20080601

• Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080515

• The effect of gastric Acid on the absorption of posaconazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080515

• Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).

  Journal of mass spectrometry : JMS 20080401

• Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

  Antimicrobial agents and chemotherapy 20080401

• Mucormycoses: serious complication of high-dose corticosteroid therapy for traumatic optic neuropathy.

  International journal of oral and maxillofacial surgery 20080401

• Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

  Therapeutic drug monitoring 20080401

• Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080315

• Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.

  Leukemia 20080301

• In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus.

  The Journal of antimicrobial chemotherapy 20080301

• Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.

  Mycoses 20080301

• Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy.

  Medical mycology 20080201

• Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.

  Antimicrobial agents and chemotherapy 20080201

• Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.

  Antimicrobial agents and chemotherapy 20080201

• Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

  Journal of clinical microbiology 20080201

• Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080201

• Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.

  Journal of the National Comprehensive Cancer Network : JNCCN 20080201

• Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint.

  Journal of the National Comprehensive Cancer Network : JNCCN 20080201

• [Antifungal activity of posaconazole and caspofungin in yeast causing invasive fungal infection (2002-2003). E-test system evaluation].

  Enfermedades infecciosas y microbiologia clinica 20080201

• Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts.

  The Journal of antimicrobial chemotherapy 20080101

• Treatment of zygomycosis: current and new options.

  The Journal of antimicrobial chemotherapy 20080101

• Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection.

  Leukemia & lymphoma 20080101

• Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

  Drugs 20080101

• Antifungal agents--clinical pharmacokinetics and drug interactions.

  Mycoses 20080101

• Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction.

  Clinical chemistry and laboratory medicine 20080101

• Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071215

• Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection.

  Medical mycology 20071201

• Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

  Pharmacotherapy 20071201

• A review of the new antifungals: posaconazole, micafungin, and anidulafungin.

  Journal of drugs in dermatology : JDD 20071201

• [Invasive zygomycosis in patients treated for haematological malignancies].

  Nederlands tijdschrift voor geneeskunde 20071124

• Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20071101

• Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.

  The Journal of antimicrobial chemotherapy 20071101

• Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.

  The Journal of antimicrobial chemotherapy 20071101

• Antifungal agents.

  The Medical journal of Australia 20071001

• Lack of cross-hepatotoxicity between voriconazole and posaconazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915

• Posaconazole therapy for chronic refractory coccidioidomycosis.

  Chest 20070901

• Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

  Antimicrobial agents and chemotherapy 20070901

• In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.

  Antimicrobial agents and chemotherapy 20070901

• Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae.

  The Journal of infection 20070901

• Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070901

• Posaconazole for invasive aspergillosis?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070901

• Recalcitrant Beauveria bassiana keratitis: confocal microscopy findings and treatment with posaconazole (Noxafil).

  Cornea 20070901

• Posaconazole: an extended-spectrum triazole antifungal agent.

  Clinical therapeutics 20070901

• In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

  Antimicrobial agents and chemotherapy 20070701

• Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

  Journal of clinical microbiology 20070601

• Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole.

  Journal of clinical microbiology 20070601

• Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

  Journal of clinical microbiology 20070601

• Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.

  Transplant infectious disease : an official journal of the Transplantation Society 20070601

• Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation.

  Transplant infectious disease : an official journal of the Transplantation Society 20070601

• Inherited long QT syndrome revealed by antifungals drug-drug interaction.

  Journal of clinical pharmacy and therapeutics 20070601

• Posaconazole: a new broad-spectrum antifungal agent.

  Expert opinion on pharmacotherapy 20070601

• Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.

  Pharmacotherapy 20070601

• Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.

  Current medical research and opinion 20070601

• Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20070601

• Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20070601

• Posaconazole: a next-generation triazole antifungal.

  Future microbiology 20070601

• Posaconazole for the management of mucosal candidiasis.

  Future microbiology 20070601

• Posaconazole prophylaxis in hematologic cancer.

  The New England journal of medicine 20070524

• Posaconazole prophylaxis in hematologic cancer.

  The New England journal of medicine 20070524

• Posaconazole prophylaxis in hematologic cancer.

  The New England journal of medicine 20070524

• Posaconazole prophylaxis in hematologic cancer.

  The New England journal of medicine 20070524

• Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes.

  Journal of clinical microbiology 20070501

• Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course.

  Journal of medical microbiology 20070501

• Mucormycosis in patients with complicated cirrhosis.

  Singapore medical journal 20070501

• Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model.

  Medical mycology 20070501

• Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods.

  Mycoses 20070501

• [Correlations among itraconazole, voriconazole and posaconazole MICs in Aspergillus fumigatus].

  Enfermedades infecciosas y microbiologia clinica 20070501

• Posaconazole for azole-refractory candidiasis in patients with HIV infection.

  AIDS alert 20070501

• Salvage treatment of histoplasmosis with posaconazole.

  The Journal of infection 20070401

• The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

  Antimicrobial agents and chemotherapy 20070401

• Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

  Journal of clinical microbiology 20070401

• Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.

  Pediatric blood & cancer 20070301

• Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

  Antimicrobial agents and chemotherapy 20070301

• Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

  Current medical research and opinion 20070301

• Posaconazole.

  Nature reviews. Drug discovery 20070301

• Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.

  Hawaii medical journal 20070301

• Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070215

• Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.

  Antimicrobial agents and chemotherapy 20070201

• Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

  Antimicrobial agents and chemotherapy 20070201

• Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature.

  Pharmacotherapy 20070201

• Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592).

  American journal of ophthalmology 20070201

• Drug approvals.

  The Nurse practitioner 20070201

• [The latest data on posaconazole].

  Medecine et maladies infectieuses 20070201

• Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.

  Journal of pediatric hematology/oncology 20070201

• Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

  The New England journal of medicine 20070125

• Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

  The New England journal of medicine 20070125

• Prophylaxis and aspergillosis--has the principle been proven?

  The New England journal of medicine 20070125

• A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.

  Journal of pharmaceutical and biomedical analysis 20070104

• Posaconazole prophylaxis in experimental systemic zygomycosis.

  Antimicrobial agents and chemotherapy 20070101

• Quality control limits for posaconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.

  Journal of clinical microbiology 20070101

• Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070101

• Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.

  HIV clinical trials 20070101

• Rhinocerebral mucormycosis with perineural spread.

  Ophthalmic plastic and reconstructive surgery 20070101

• Changing epidemiology of rare mould infections: implications for therapy.

  Drugs 20070101

• Update on new antifungal therapy.

  AACN advanced critical care 20070101

• Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant.

  Pediatric blood & cancer 20061201

• Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

  Antimicrobial agents and chemotherapy 20061201

• Posaconazole (Noxafil) for invasive fungal infections.

  The Medical letter on drugs and therapeutics 20061120

• Evaluation of automated micro solid phase extraction tips (micro-SPE) for the validation of a LC-MS/MS bioanalytical method.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061107

• Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.

  Antimicrobial agents and chemotherapy 20061101

• Chronic refractory phaeohyphomycosis: successful treatment with posaconazole.

  Mycoses 20061101

• Multi-azole resistance in Aspergillus fumigatus.

  International journal of antimicrobial agents 20061101

• New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061015

• Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

  Journal of clinical microbiology 20061001

• Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis.

  Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 20060901

• Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20060901

• Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.

  The Annals of thoracic surgery 20060701

• Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

  Antimicrobial agents and chemotherapy 20060701

• Periorbital zygomycosis (mucormycosis) treated with posaconazole.

  American journal of ophthalmology 20060701

• First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole.

  The American journal of the medical sciences 20060701

• Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060615

• Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors.

  International journal of antimicrobial agents 20060601

• Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.

  Antimicrobial agents and chemotherapy 20060601

• In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

  Antimicrobial agents and chemotherapy 20060601

• In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

  Antimicrobial agents and chemotherapy 20060601

• Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.

  Expert opinion on investigational drugs 20060601

• Importance of identification of zygomycetes in the era of newer antifungal agents.

  Transplant infectious disease : an official journal of the Transplantation Society 20060601

• Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

  Journal of clinical microbiology 20060601

• Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060515

• Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

  Antimicrobial agents and chemotherapy 20060501

• Control of a Candida glabrata prosthetic endovascular infection with posaconazole.

  Medical mycology 20060501

• A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060415

• Oropharyngeal candidiasis: a new treatment option.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060415

• Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060401

• Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

  Antimicrobial agents and chemotherapy 20060301

• Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method.

  Antimicrobial agents and chemotherapy 20060301

• Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.

  Journal of medicinal chemistry 20060209

• Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

  Antimicrobial agents and chemotherapy 20060201

• Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

  Bioorganic & medicinal chemistry letters 20060101

• Posaconazole as salvage therapy for zygomycosis.

  Antimicrobial agents and chemotherapy 20060101

• Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20060101

• Use of posaconazole in the management of invasive orbital aspergillosis in a cat.

  Journal of the American Animal Hospital Association 20060101

• A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.

  Mycoses 20060101

• Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.

  Mycoses 20060101

• HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.

  Mycoses 20060101

• Second-line treatment in invasive mould infections.

  Mycoses 20060101

• Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

  Mycoses 20060101

• Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia.

  Mycoses 20060101

• Posaconazole for treatment of refractory invasive fungal disease.

  Mycoses 20060101

• Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.

  Mycoses 20060101

• New drugs: ranibizumab, posaconazole, and darunavir.

  Journal of the American Pharmacists Association : JAPhA 20060101

• Novel medicine to prevent fungal infections.

  FDA consumer 20060101

• Posaconazole: a broad-spectrum triazole antifungal.

  The Lancet. Infectious diseases 20051201

• Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy.

  Transplantation 20051115

• Posaconazole therapy for systemic coccidioidomycosis in a chimpanzee (Pan troglodytes): a case report.

  Mycoses 20051101

• Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.

  Haematologica 20051101

• What does 'culture of life' mean for an undocumented immigrant?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051015

• Activity of posaconazole in the treatment of central nervous system fungal infections.

  The Journal of antimicrobial chemotherapy 20051001

• Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.

  Journal of clinical microbiology 20051001

• Advances in antifungal therapy.

  The Pediatric infectious disease journal 20051001

• Absidia posttraumatic infection: successful treatment with posaconazole.

  The Journal of infection 20051001

• A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole.

  The Journal of infection 20051001

• Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.

  Clinical advances in hematology & oncology : H&O 20051001

• Review of treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.

  Clinical advances in hematology & oncology : H&O 20051001

• Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

  Journal of clinical microbiology 20050901

• [Physiological comportment and in vivo sensitivity of Sporothrix schenckii isolates maintained for 18 years by two preservation methods].

  Revista iberoamericana de micologia 20050901

• Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy.

  Transplantation 20050827

• In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.

  Antimicrobial agents and chemotherapy 20050801

• International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

  Journal of clinical microbiology 20050801

• Lung infection due to opportunistic fungus, Phialemonium obovatum, in a bone marrow transplant recipient: an emerging infection with fungemia and Crohn disease-like involvement of the gastrointestinal tract.

  Annals of diagnostic pathology 20050801

• Posaconazole: clinical pharmacology and potential for management of fungal infections.

  Expert review of anti-infective therapy 20050801

• Refractory coccidioidomycosis treated with posaconazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615

• Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.

  The Journal of antimicrobial chemotherapy 20050601

• Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050601

• Antifungal agents in children.

  Pediatric clinics of North America 20050601

• Posaconazole.

  Drugs of today (Barcelona, Spain : 1998) 20050601

• In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.

  Medical mycology 20050501

• Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.

  The Journal of antimicrobial chemotherapy 20050301

• In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.

  Medical mycology 20050301

• Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

  Journal of clinical pharmacology 20050201

• Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

  Antimicrobial agents and chemotherapy 20050201

• Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing.

  Journal of clinical microbiology 20050201

• Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole.

  Medical mycology 20050201

• Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

  Clinical pharmacokinetics 20050101

• Posaconazole.

  Drugs 20050101

• Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.

  Revista do Instituto de Medicina Tropical de Sao Paulo 20050101

• Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20041201

• Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.

  Cancer 20041001

• Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

  Antimicrobial agents and chemotherapy 20041001

• Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

  Antimicrobial agents and chemotherapy 20041001

• Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

  Antimicrobial agents and chemotherapy 20041001

• Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

  Journal of clinical microbiology 20041001

• Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

  Antimicrobial agents and chemotherapy 20040901

• Disposition of posaconazole following single-dose oral administration in healthy subjects.

  Antimicrobial agents and chemotherapy 20040901

• Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20040901

• Alternatives to amphotericin B for Candida rugosa infection.

  The Journal of antimicrobial chemotherapy 20040801

• Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

  Antimicrobial agents and chemotherapy 20040801

• Challenges in designing animal studies to detect antagonism of polyene activity.

  Antimicrobial agents and chemotherapy 20040801

• Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.

  Journal of clinical microbiology 20040801

• Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

  Antimicrobial agents and chemotherapy 20040601

• Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

  Antimicrobial agents and chemotherapy 20040601

• Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

  International journal of clinical practice 20040601

• Posaconazole therapy for severe abdominal candidiasis: a case report.

  Revista iberoamericana de micologia 20040601

• [Fulminant invasive fungal sinusitis in immunosuppressed hosts -- pathognomic presentation in MRI].

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20040501

• Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20040401

• Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

  Antimicrobial agents and chemotherapy 20040301

• Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.

  Antimicrobial agents and chemotherapy 20040301

• Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole.

  Journal of clinical microbiology 20040301

• In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

  Diagnostic microbiology and infectious disease 20040301

• Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040201

• Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

  Antimicrobial agents and chemotherapy 20040201

• Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

  Drug metabolism and disposition: the biological fate of chemicals 20040201

• Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

  British journal of clinical pharmacology 20040201

• Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

  The Journal of antimicrobial chemotherapy 20040101

• Reversible dilated cardiomyopathy related to amphotericin B therapy.

  The Journal of antimicrobial chemotherapy 20040101

• Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

  Antimicrobial agents and chemotherapy 20040101

• In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

  Revista iberoamericana de micologia 20031201

• Activity of posaconazole in treatment of experimental disseminated zygomycosis.

  Antimicrobial agents and chemotherapy 20031101

• Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

  Antimicrobial agents and chemotherapy 20030901

• [Invasive aspergillosis: clinical manifestations and treatment].

  Revista iberoamericana de micologia 20030901

• Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

  Journal of clinical microbiology 20030801

• New antifungal agents.

  Dermatologic clinics 20030701

• Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20030601

• Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.

  Antimicrobial agents and chemotherapy 20030401

• In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs.

  Diagnostic microbiology and infectious disease 20030401

• Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma.

  Journal of chromatography. A 20030214

• Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

  Antimicrobial agents and chemotherapy 20030201

• In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

  Journal of clinical microbiology 20030101

• Posaconazole: SCH 56592.

  Drugs in R&D 20030101

• [In vitro activity of posaconazole against yeasts isolated in blood cultures].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20021201

• [Present status and future prospects of azole antifungal agents in Japan].

  The Japanese journal of antibiotics 20021201

• Laboratory evaluation of new antifungal agents against rare and refractory mycoses.

  Current opinion in infectious diseases 20021201

• In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).

  Mycoses 20021101

• Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20021101

• In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.

  Antimicrobial agents and chemotherapy 20021001

• Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.

  Antimicrobial agents and chemotherapy 20020701

• In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

  Antimicrobial agents and chemotherapy 20020701

• Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.

  The British journal of ophthalmology 20020701

• In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.

  The Journal of antimicrobial chemotherapy 20020701

• Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020615

• E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

  Journal of clinical microbiology 20020601

• Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.

  Journal of chemotherapy (Florence, Italy) 20020601

• In vitro and in vivo activities of posaconazole against Coccidioides immitis.

  Antimicrobial agents and chemotherapy 20020501

• Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.

  Journal of clinical microbiology 20020501

• Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

  Antimicrobial agents and chemotherapy 20020401

• Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates.

  Archives of oral biology 20020301

• Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis.

  Journal of mass spectrometry : JMS 20020301

• Azole cross-resistance in Aspergillus fumigatus.

  Antimicrobial agents and chemotherapy 20020201

• Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma.

  Journal of pharmaceutical and biomedical analysis 20020101

• Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.

  The Journal of antimicrobial chemotherapy 20011201

• Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.

  Diagnostic microbiology and infectious disease 20011201

• Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

  Journal of clinical microbiology 20011101

• In vitro activity of posaconazole against clinical isolates of dermatophytes.

  Journal of clinical microbiology 20011101

• In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.

  Antimicrobial agents and chemotherapy 20011001

• Antifungals: what's in the pipeline.

  Current opinion in microbiology 20011001

• In vitro antifungal activity of posaconazole against various pathogenic fungi.

  International journal of antimicrobial agents 20010801

• In vitro activities of four novel triazoles against Scedosporium spp.

  Antimicrobial agents and chemotherapy 20010701

• Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS.

  Journal of pharmaceutical and biomedical analysis 20010601

• Treatment of histoplasmosis.

  Seminars in respiratory infections 20010601

• Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

  Antimicrobial agents and chemotherapy 20010501

• Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

  Antimicrobial agents and chemotherapy 20010301

• Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20010301

• In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

  Antimicrobial agents and chemotherapy 20000801

• In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.

  Antimicrobial agents and chemotherapy 20000101

• In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.

  The Journal of antimicrobial chemotherapy 19991201

• [New antifungal drugs. Present and future].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 19990901

• Current and emerging azole antifungal agents.

  Clinical microbiology reviews 19990101

• In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

  Antimicrobial agents and chemotherapy 19981201

• Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

  Journal of clinical microbiology 19981001

• SCH56592 treatment of murine invasive aspergillosis.

  The Journal of antimicrobial chemotherapy 19981001

• In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi.

  Mycopathologia 19980101

• Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

  Antimicrobial agents and chemotherapy 19971001

• Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

  Antimicrobial agents and chemotherapy 19970201

• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

  Antimicrobial agents and chemotherapy 19970101

• In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

  Antimicrobial agents and chemotherapy 19960801